CD4
T-cell surface glycoprotein CD4
Also known as: CD4_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01730
- Gene
- CD4
- Ensembl
- ENSG00000010610
- Chromosome
- 12
- Canonical length
- 458 aa
- Protein class
- CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, May 2020]
Canonical amino-acid sequenceUniProt
458 residues, UniProt reviewed canonical sequence.
>P01730|CD4
1 MNRGVPFRHL LLVLQLALLP AATQGKKVVL GKKGDTVELT CTASQKKSIQ FHWKNSNQIK
61 ILGNQGSFLT KGPSKLNDRA DSRRSLWDQG NFPLIIKNLK IEDSDTYICE VEDQKEEVQL
121 LVFGLTANSD THLLQGQSLT LTLESPPGSS PSVQCRSPRG KNIQGGKTLS VSQLELQDSG
181 TWTCTVLQNQ KKVEFKIDIV VLAFQKASSI VYKKEGEQVE FSFPLAFTVE KLTGSGELWW
241 QAERASSSKS WITFDLKNKE VSVKRVTQDP KLQMGKKLPL HLTLPQALPQ YAGSGNLTLA
301 LEAKTGKLHQ EVNLVVMRAT QLQKNLTCEV WGPTSPKLML SLKLENKEAK VSKREKAVWV
361 LNPEAGMWQC LLSDSGQVLL ESNIKVLPTW STPVQPMALI VLGGVAGLLL FIGLGIFFCV
421 RCRHRRRQAE RMSQIKRLLS EKKTCQCPHR FQKTCSPILocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 204 nTPM
Expression across tissuesHPA
Tissue
- thymus: 204 nTPM
- parathyroid gland: 164 nTPM
- spleen: 155 nTPM
- liver: 143 nTPM
- lymph node: 112 nTPM
- appendix: 78 nTPM
Single-cell type
- kupffer cells: 559 nCPM
- pdcs: 315 nCPM
- hofbauer cells: 224 nCPM
- macrophages: 175 nCPM
- cdc: 136 nCPM
- microglia: 131 nCPM
Immune cell
- plasmacytoid DC: 264 nTPM
- classical monocyte: 247 nTPM
- intermediate monocyte: 241 nTPM
- total PBMC: 240 nTPM
- non-classical monocyte: 205 nTPM
- myeloid DC: 166 nTPM
Brain region
- white matter: 35 nTPM
- medulla oblongata: 30 nTPM
- pons: 24 nTPM
- spinal cord: 22 nTPM
- thalamus: 22 nTPM
- midbrain: 17 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CD4.
Disease | AllUniProt
Conditions CD4 is implicated in, by any mechanism.
- Immunodeficiency 79 (IMD79) MIM:619238
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 63 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Immunodeficiency 79
Disease | AutoantibodyPubMed
Conditions in which antibodies against CD4 are reported. Each links to that disease's full target list.
- HIV Infections 32
- Lupus Erythematosus, Systemic 11
- Acquired Immunodeficiency Syndrome 7
- Arthritis, Rheumatoid 7
- Diabetes Mellitus, Type 1 7
- Proteinuria 6
- Vasculitis 5
- Glomerulonephritis 4
- Antiphospholipid Syndrome 3
- Encephalomyelitis, Autoimmune, Experimental 3
- Thyroiditis, Autoimmune 3
Showing 11 of 15 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for CD4 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
134 publications
- Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells.
1989 · J Autoimmun · RCR 4.4 · 169 citations - Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.
2013 · J Immunol · RCR 3.6 · 134 citations - Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.
1996 · J Clin Invest · RCR 3 · 167 citations - Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced HIV.
2025 · Clin Infect Dis · RCR 3 · 8 citations - Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice.
1997 · Kidney Int · RCR 2.9 · 140 citations
Show 20 more of 134 total
- WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity.
2011 · J Exp Med · RCR 2.7 · 134 citations - Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice.
1994 · Diabetes · RCR 2.6 · 119 citations - IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice.
1998 · Clin Exp Immunol · RCR 2.5 · 122 citations - T cell recognition of allopeptides in context of syngeneic MHC.
1992 · J Immunol · RCR 2.4 · 118 citations - Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner.
2011 · Arthritis Rheum · RCR 2.4 · 99 citations - CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
2003 · J Clin Invest · RCR 2.4 · 148 citations - Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice.
1997 · J Exp Med · RCR 2.4 · 126 citations - T-Lymphocyte Subset Distribution and Activity in Patients With Glaucoma.
2019 · Invest Ophthalmol Vis Sci · RCR 2.3 · 47 citations - Detection of anti-CD4 autoantibodies in the sera of HIV-infected patients using recombinant soluble CD4 molecules.
1988 · AIDS · RCR 1.7 · 74 citations - Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.
2004 · J Autoimmun · RCR 1.7 · 90 citations - Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1.
1989 · Proc Natl Acad Sci U S A · RCR 1.5 · 72 citations - Antibodies to soluble CD4 in HIV-1-infected individuals.
1988 · AIDS · RCR 1.5 · 60 citations - Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens.
2002 · J Autoimmun · RCR 1.4 · 56 citations - Autoantibodies against CD4 cells are associated with CD4 helper defects in human immunodeficiency virus-infected patients.
1991 · Blood · RCR 1.4 · 59 citations - Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice.
1992 · Cell Immunol · RCR 1.4 · 74 citations - The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies.
2001 · Semin Arthritis Rheum · RCR 1.3 · 63 citations - Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
1993 · J Immunol · RCR 1.2 · 61 citations - Mechanisms of immune injury in rheumatoid arthritis: evidence for the involvement of T cells and heat-shock protein.
1990 · Immunol Rev · RCR 1.2 · 53 citations - Detection and epitope analysis of autoantigen-reactive T cells to the U1-small nuclear ribonucleoprotein A protein in autoimmune disease patients.
1993 · J Immunol · RCR 1.2 · 57 citations - B-cell activation following murine cytomegalovirus infection: implications for autoimmunity.
1993 · Immunology · RCR 1.2 · 42 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.71
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.06
- DepMap mean gene effect
- 0.03
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- calcium-mediated signaling
- cell adhesion
- cell surface receptor protein tyrosine kinase signaling pathway
- cell surface receptor signaling pathway
- cellular response to granulocyte macrophage colony-stimulating factor stimulus
- cellular response to ionomycin
- defense response to Gram-negative bacterium
- enzyme-linked receptor protein signaling pathway
- immune response
- interleukin-15-mediated signaling pathway
- macrophage differentiation
- maintenance of protein location in cell
- positive regulation of calcium ion transport into cytosol
- positive regulation of calcium-mediated signaling
- positive regulation of interleukin-2 production
- positive regulation of monocyte differentiation
- positive regulation of T cell proliferation
- regulation of T cell activation
- response to estradiol
- response to ethanol
- response to methamphetamine hydrochloride
- response to vitamin D
- signal transduction
- symbiont entry into host cell
- T cell differentiation
- T cell receptor signaling pathway
- T cell selection
- helper T cell enhancement of adaptive immune response
Molecular functions
- coreceptor activity
- enzyme binding
- extracellular matrix structural constituent
- identical protein binding
- immunoglobulin binding
- lipid binding
- MHC class II protein binding
- MHC class II protein complex binding
- protein homodimerization activity
- protein kinase binding
- protein tyrosine kinase binding
- signaling receptor activity
- transmembrane signaling receptor activity
- virus receptor activity
- zinc ion binding
- interleukin-16 binding
- interleukin-16 receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Immunoglobulin C2-set
- Immunoglobulin V-set domain
- Immunoglobulin-like beta-sandwich domain
- Immunoglobulin-like fold
- Immunoglobulin-like domain superfamily
- Immunoglobulin domain
- Immunoglobulin C2-set domain
- T-cell surface antigen CD4
- CD4, extracellular
- T cell CD4 receptor C-terminal region
- CD4, extracellular
- T cell CD4 receptor C terminal region
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CD4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD4 as an antibody target. Whether an autoantibody or antibody against CD4 could matter depends on whether native CD4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD4 is annotated at the cell surface, where native CD4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...